Moving to Remodulin, we reported fourth-quarter worldwide ... RemUnity Pro is the next generation in subcutaneous pump technology optimized and designed for patients with PAH.

In the 10-K report, Liquidia Corporation reported a net loss of $130.4 million for the year ended December 31, 2024, compared ...

Optum Rx has eliminated reauthorization for almost 70 drugs for chronic diseases, about 10% of its overall pharmacy prior ...

BERLIN — Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the ...

United Therapeutics (NASDAQ:UTHR) Corporation reported its fourth-quarter 2024 earnings, revealing a notable miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS ...

Treprostinil sodium, which has a metabolic half-life of two to four hours, is supplied as a solution in 20-mL multiple-entry vials for continuous subcutaneous administration at room temperature.

The increase in share-based compensation expense for the quarter ended December 31, 2024, as compared to the same period in 2023, was primarily due to: (1) an increase in stock option expense due ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

The places where you inject insulin may depend on the type of syringe or prefilled insulin pen you use. You should rotate these injection sites on your skin each time you inject insulin. There are ...

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).